Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency

Trial Profile

Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MB 107 (Primary) ; Busulfan; Palifermin
  • Indications Immunodeficiency disorders; X-linked genetic disorders
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 09 Dec 2019 Results published in Mustang Bio Media Release
    • 09 Dec 2019 According to a Mustang Bio media release, data from the trial were presented at the 61st American Society of Hematology (ASH) Annual Meeting.
    • 19 Nov 2019 Planned number of patients changed from 20 to 30.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top